• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Oncology division





























What’s with you and GSK?
Eisai oncology reps do not go to the desirable biotech oncology companies...they go to Merck, GSK, Novartis, Pfizer, etc. - the places no one wants to go. I believe that is what the poster meant but saying GSK. So basically you go from a midsized crappy company to a big crappy company.
 








I have friends at Novartis, Merck, and GSK. They are all very happy so…..
All the companies are the same really. Just get as much money as you can and a decent manager
This is a classic example of “you don’t know what you don’t know”…

All of those companies pay low and have a ton of micromanagers.